0
Applied AI·October 28, 2026·1 min read

Anthropic buys a one-person biotech and starts its own drug programmes

Share

An AI lab acquiring a one‑person biotech to run its own rare‑disease programs is a verticalization move—owning both the model and the therapeutic pipeline. If you’re in life sciences, assume the frontier labs may become direct competitors for certain indications, not just tooling vendors.